Administrative (Include Year, Position, and Institution):

2001 - 2004     Representative, Faculty Senate Assembly, University of Michigan

2001 - 2004     Co-director, Cutaneous T-cell Lymphoma Program, University of Michigan

2018-               Co-Chair, Clinical Knowledge and Therapeutics Executive Committee – Oncology subcommittee

Other (Include Year, Position, and Institution):

IV.  SCHOLARSHIP

Area(s) of Research/Scholarly Interest:  My clinical and research are focused on lymphoma with a special emphasis on T cell lymphomas and immunotherapy.

Grants and Contracts:

Federal (Include Title, Source, PI, Amount Period, and % Effort)

Title: “Tumor TCR Idiotype Vaccines for Active Immunotherapy of T Cell Cancers”
Source: Veterans Affairs MERIT Review Award
Principal Investigator: Craig Okada
Amount of $591,700 (direct costs)
Period: 9/01 - 8/05
Effort: 35%

State and Local (Include Title, Source, PI, Amount Period, and % Effort)

Title: “Development of T cell tumor TCR Id vaccines for clinical studies”
Source: Veterans Education and Research Association of Michigan 
Principal Investigator: Craig Okada
Amount: $15,000 (direct costs)
Period: 6/1999 - 5/2000
Effort: 20%

Title: “Enhanced Dendritic Cell Vaccine Efficacy by Improving Lymph Node Homing” Source: Medical Research Foundation of Oregon
Principal Investigator: Craig Okada
Amount of $30,000 (direct costs)
Period: 6/05 - 5/06
Effort: 35%

Other Support (Include Title, Source, PI, Amount Period, and % Effort)

Title: “Development of T Cell Tumor TCR Id Vaccines”
Source: American Cancer Society Institutional Award
Principal Investigator: Craig Okada
Amount: $25,000 (direct costs)
Period: 7/1999 - 6/01
Effort: 25%

Title: “Tumor Antigen Receptor Vaccines for Active Immunotherapy of T Cell
            Malignancies”
Source: The G & P Charitable Foundation for Cancer Research
Principal Investigator: Craig Okada
Amount: $150,000 (direct costs)
Period: 8/1999 - 7/2002
Effort: 20%

Title: “Treatment of T cell Lymphomas with T Cell Receptor Specific Antibodies and
            Vaccines”
Source: Leukemia & Lymphoma Society
Principal Investigator: Craig Okada
Amount: $411,200 (direct costs)
Period: 10/2006 - 9/2011
Effort: 20%

Pending Support (Include Title, Source, PI, Amount Period, and % Effort)

Publications/Creative Work:

Peer-reviewed

1. Elliot GC, Ajioka J and Okada CY.  A rapid procedure for assaying nicotinamide phosphoribosyltransferase.  Anal. Biochem. (1980) 107:199 - 205.
2. Okada CY and Rechsteiner M.  Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles.  Cell (1982) 29:33 - 41.
3. Barth RK, Kim BS, Lan NC, Hunkapiller T, Sobieck N, Winoto A, Gershenfeld H, Okada CY, Hansberry D, Weissman I and Hood L.  The murine T - cell receptor uses a limited repertoire of expressed Vb gene segments.  Nature (Lond.) (1985) 316:517 - 23.
4. Mueller C, Gershenfeld HK, Lobe CG, Okada CY, Bleackley RC and Weissman IL.  Expression of two serine esterase genes during an allograft rejection in the mouse.  Transplant Proc. (1988) 20:251 - 53.
5. Mueller C, Gershenfeld HK, Lobe CG, Okada CY, Bleackley RC and Weissman IL.  A high proportion of T-lymphocytes that infiltrate H-2 incompatible heart allografts in vivo express genes encoding cytotoxic T cell specific serine prote­ases, but do not express the MEL-14 - defined lymph node homing receptor.  J. Exp. Med. (1988) 167:1124 - 36.
6. Okada CY and Weissman IL.  Relative Vb transcript levels in thymus and pe­ripheral lymphoid tissues from various mouse strains.  Inverse correlation of IE and Mls expression with relative abundance of several Vb_ transcripts in peripheral lymphoid tissues.  J. Exp. Med. (1989) 169:1703 - 1719.
7. Okada CY, Holzmann B, Guidos C, Palmer E and Weissman IL.  Characterization of a rat monoclonal antibody specific for a determinant encoded by the Vb7 gene segment.  Depletion of Vb7+ T-cells in mice with Mls-1a haplotype.  J. Immun. (1990) 144:3473 - 3477.
8. Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, and Levy R.  Rationale for adjuvant idiotypic vaccination after high dose therapy for multiple myeloma.  Biol Blood Marrow Transplant (1997) 3:157 - 163.
9. Okada CY, Wong CP, Denney DW and Levy R.  T cell antigen receptor vaccines for active immunotherapy of T cell malignancies.  J. Immun. (1997) 159:5516 - 5527.
10. Wong CP, Okada, CY and Levy R.  TCR vaccines against T cell lymphoma:  QS-21 and IL-4 adjuvants induce a protective CD8⁺ T cell response.  J. Immun. (1999) 162:2251 - 2258.
11. Reichardt, VL, Okada CY, Liso A, Benike C, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R.  Idiotype vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation.  Blood (1999) 93:2411 - 2419.
12. Lossos, IS, Okada CY, Tibshirani R, Warnke R, Vose JM, Greiner TC, Allen J, and Levy R.  Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas.  Blood (2000) 95:1797 - 1803
13. Reddy SA. Okada C, Wong C, Bahler D, Levy R. T cell antigen receptor vaccines for active therapy of T cell malignancies.  Annals of the New York Academy of Sciences (2001) 941:97- 105.
14. Timmerman JT, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, and Levy R.  Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.  Blood (2002) 99: 1517 - 1526
15. Gatza E and Okada CY.  Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.  J. Immun.  (2002) 169:5227 - 5235
16. Lambert SL, Okada CY, Levy R.  TCR vaccines against a murine T cell lymphoma:  A primary role for antibodies of the IgG2c class in tumor protection.  J. Immunol.  (2004) 172:929 - 936
17. Lau JJ. Okada CY. Trobe JD. Galloping ophthalmoplegia and numb chin in Burkitt lymphoma. J. Neuro-Ophth. (2004) 24(2):130 - 4.
18. Gatza E and Okada CY. Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for T cell lymphoma.  Cancer Immunology & Immunotherapy (2006) 55(4):420 - 32. (UI: 16025264)
19. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, and Shuman M. Gene expression and angiotropism in primary CNS lymphoma.  Blood (2006) 107: 3716 - 3723. (UI: 16418334)
20. Spurgeon SE, Pindyck T, Okada C, Chen Y, Chen Z, Mater E, Abbi K and Epner EM. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leukemia and Lymphoma (2011) 52(8): 1488 – 1494. (UI: 21623691)
21. Smith SD, Chen A, Spurgeon S, Okada C, Fan G, Dunlap J, Braziel R and maziar R.  Diffuse large B cell lymphoma in adults aged 75 years and older: a single institution analysis of cause-specific survival and prognostic factors. Therapeutic Advances in Hematology (2013) 4(6):349-53
22. Chen AI, Okada C, Gay N, Reiss P, Spurgeon S, Fan G, Braziel RM and Maziarz RT. Consolidative autologous stem cell transplant for double hit lymphoma. Blood (2014) 3993-
23. Gay ND, Okada CY, Chen AI and Scott EC. Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab. Therapeutic Advances in Hematology (2017) 8(5):175-180). PMID: 28473905
24. Chen, AI, Leonard, JT, Okada, CY, Gay ND, Chansky, K, Fan G, Dunlap JB and Raess, PW. Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma. Leukemia & Lymphoma (2018) 59:1884-1889. PMID: 29199519
25. Gay ND, Kozin E. Okada C, Danilov AV, and Spurgeon S. Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia. Leukemia & Lymphoma (2018) 59:2258-2260 PMID 29249186
26. Gay ND, Chen, A and Okada CY. Colorectal lymphoma: a review. Clinics in Colon and Rectal Surgery. (2018) 31:309-315
27. Best S, Hashiguchi T, Kittai A, Bruss N, Paiva C, Okada C, Liu T, Berger A and Danilov AV. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells. Blood Advances (2019) 3:51-62. PMID 2018026880
28. Johnson LDS, Banerjee S. Kruglov O, Viller NN, Horwitz SM, Lesokhin A, Zain J, Quefeld C, Chen R, Okada C, Sawas A, O’Connor OA, Sievers EL, Shou Y, Uger RA, Wong M, Akilov OE. Targeting CD47 in Sezary syndrome with SIRPalphaFC. (2019) Blood Advances 3(7):1145-1153
29. Willis A, Fan G, Kim E, Okada CY, White KP and Hopkins RS. Primary cutaneous Epstein-Barr virus-positive diffuse large B cell lymphoma (DLBCL) in a patient taking fingolimod. Dermatology Online Journal. 25(9), 2019 Sep 15
30. Hashiguchi T, Bruss N, Lam V, Danilova O, Paiva CJ, Wolf J, Bilvert EW, Okada CY, Kaur P, Drew L, Cidado J, Hurlin P and Danilov AV. Cyclin-Dependent Kinase-9 is a therapeutic taret in Myc-expressing diffuse large B cell lymphoma. Molecular Cancer Therapeutics (2019) 18(9):1520-1532
31. Johnson LDS, Banerjee S, Kruglov O, Viller NN, Horwitz SM, Lesokhin A, Zain J, Quefield C, Chen R, Okada C, Sawas A, O’Connor OA, Sievers EL, Shou Y, Uger RA, Wong M, Akilov DE. Targeting CD47 in Sezary syndrome with SIRPalphaFc.  Blood Advances. (2019) 3(7);1145-1153
32. Raghunathan V, Fan G, Kittai AS, Okada C, Danilov AV, Spurgeon SE. A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia. (2020) European Journal of Haematology Epub Ahead of Print. Web. 11 January. 2021

Non-peer-reviewed: none

Books: none

Chapters

1. Okada CY, Traer E and Dunlap J. Classical Hodgkin Lymphoma with Paraneoplastic Neruomytonia. In Case Studies in Hematology and Coagulation. p216 - 218. Ed: Gulati G, O’Hara JF and Krause JR. AACP Press 2012
2. Okada CY, Gang XU. Lymphocyte-Rich Classical Hodgkin Lymphoma. In Case Studies in Hematology and Coagulation. p222 - 224. Ed: Gulati G, O’Hara JF and Krause JR. AACP Press 2012

Electronic Publications: none

Reviews

1. Adkins B, Mueller C, Okada CY, Reicherst RA, Weissman IL and Spangrude GJ.  Early events in T-cell maturation.  Ann. Rev. Immunol. (1987) 5:325 - 65.
2. Okada C, New small lymphocytic lymphomas.  Michigan Oncology Journal Fall, 2000:8 - 10

Abstracts

1. Duvic M, Vanaclocha F, Bernengo MG, Okada C, Breneman D, Zinzani PL, Zhang L, Bopp K, Laird G, Harawat S and Prince M. Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory cutaneous T cell lymphoma (CTCL). ASCO (2008) J. Clin. Oncol. 26 Absr 8555
2. Pindyck T, Spurgeon SE, Okada CY and Epner EE. Cladribine plus rituximab for the initial treatment of mantle cell lymphoma.  ASCO (2010) J. Clin. Oncol 28:15s abstr 8099.
3. Spurgeon SE, Okada CY, Huang J, Phillips J, and Epner EE. Targeting the epigenome: A phase I/II study of vorinostat (SAHA), CLADRIBINE (2-CDA), and rituximab in relapsed B cell malignancies. ASCO (2010) J. Clin. Oncol 28: 15s Absr TPS301
4. Spurgeon S, Pindyck T, Loriaux MM, Okada C, Abbi K, Chen Y, Chen Z, Mater E and Epner E. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Blood 2010, 116: Abs 4910
5. Crump M, Scheliga A, Mayer J, Offner F, Teixeira A, Kuliczdowski K, Liberati AM, Okada C, Esseltine D-L, Enny C, Zhu E. van de Velde H, Elsayed YA, and Coiffier B. Efficacy and safety of bortezomib-rituximab (VcR) vs rituximab (R) in patients (pts) with relapsed, R-naïve/-sensitive follicular lymphoma (FL) who had received 1 or 2 prior lines of therapy. ICML 2011 congress
6. Kimby E, Scheliga A, Mayer J, Offner F, Teixeira A, Kuliczdowski K, Liberati AM, Okada C, Esseltine D-L, Theocharous P, Zhu E. van de Velde H, Elsayed YA, and Coiffier B. Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VcR) vs rituximab (R) in patients (pts) with relapsed follicular lymphoma (FL). ICML 2011 congress
7. Zinzani PL, Khuageva NK, Wang H, Garikochea B, VanHoof A, Soubeyran P, Caballero D, Okada C, Buckstein R, Esseltine D-L, Theocharous P, Zhu E, Eenny C, Elsayed YA, and Coiffier B. Bortezomib plus rituximab (VcR) vs rituximab alone (R) in patients (pts) with high-risk, relapsed, R-naïve/-sensitive follicular lymphoma (FL). ICML 2011 congress
8. Spurgeon S. Chen AI, Okada C, Parekh S, Leshchenko VV, Palmbach G, Ratterree B, Subbiah N, Capper C, and Epner EM. A phase I/II study of vorinostat (SAHA), cladribine (2-CdA), and rituximab shows significant activity in previously untreated mantle cell lymphoma. Blood 2011, 118: Abstr 441.
9. Smith SD, Okada C, Chen AI, Spurgeon SE, Fan G, Dunlap JB, Leeborg N, Braziel RM and Maziarz RT. Prognostic features, treatments and disease-specific mortality among patients with diffuse large B-cell lymphoma over the age of 75: A single-center retrospective analysis. Blood 2012, 120: abstr 3673
10. Flowers, C Panizo C, Isufi I, Herrera F, Okada C, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J Chau I, von Keudell GR, Lu H, Hsu FJ and Halwani AS. Blood 2017, 130:2771

Other

Clinical Investigation Activities (Principle Investigator Only)

1999 - 2004      “A Phase 3 Trial to Evaluate the Safety and Efficacy of Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH with GM-CSF, Compared to Non-Specific Immunotherapy, KLH with GM-CSF, in Patients with Follicular Non-Hodgkin’s Lymphoma” Sponsor: Genitope Corp.

2007 - 2009      “Hx-CD4-110: Open-label, Dose escalation, followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides type CTCL (stage IB-IVB) who are Refractory or Intolerant to Targretin® (bexarotene) and one other Standard Therapy” Sponsor: GenMab

2007 - 2009      “A Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-Cell Lymphoma” Sponsor: Novartis

2007 - 2008      “Favid-06: A Phase III, Randomized, Double Blind, Placebo Controlled Trial of Favid and GM-CSF versus Placebo and GM-CSF Following Rituximab in Subjects with Follicular B-Cell Non-Hodgkin’s Lymphoma” Sponsor: Favrille

2007 - 2008      “Favid-09: A Phase II Trial of Favid (Patient-Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive Favid on Study Favid-06” Sponsor: Favrille

2007 - 2010      “E4494: Phase III Trial of CHOP versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients with Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin’s Lymphoma” Sponsor: SWOG

2007 - 2010      “A Randomized, Open-Label Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab Naïve or Sensitive Follicular B-Cell Non-Hodgkin’s Lymphoma” Sponsor: Johnson & Johnson Pharmaceutical

2007 - 2008      “S9911: A Phase II Pilot Trial of CHOP Followed By Iodine-131-Labeled Monoclonal Anti-B1 Antibody For Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphomas” Sponsor: SWOG

2007 - 2010      “A Double-Blind, Randomized, Two-Dose-Arm, Parallel Group, International, Multi-Center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients with Follicular Lymphoma who are Refractory to Rituximab in combination with Chemotherapy” Sponsor: Genmab, Inc.

2008 - 2011      “An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High Risk Diffuse Large B-Cell Lymphoma”  Sponsor: Eli Lilly and Company

2008 - 2011      “S8819: Central Lymphoma Repository Tissue Procurement Protocol. A companion Protocol.” Sponsor: SWOG

2008 - 2010      “A Phase I/II Study of Oral Clofarabine + Rituximab in Relapsed B Cell NHL” Sponsor: Genzyme

2010 - 2011      “An Open-Label Study to Evaluate the Efficacy and Safety of Treatment with Bendamustine in Combination with Ofatumumab in Previously Untreated Patients with Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)”  Sponsor: Cephalon

2011 - 2013      “Phase II trial of ofatumumab and bortezomib in subjects with relapsed CD20+ Diffuse Large B Cell Lymphoma, Follicular Lymphoma, or Mantle Cell Lymphoma” Investigator Initiated study. Support: GSK

2011 - 2017      “A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging” Sponsor: SWOG

2011 - 2017      “Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomograph for Non-Bulky Stage I and II Hodgkin Lymphoma” Sponsor: CALGB

2015- 2019       “Phase 1/2 Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma” Sponsor: Immune Design

2018 - ongoing “A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors” Sponsor: Trillium Therapeutics Inc

2018 - ongoing “A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B cell Lymphoma” Sponsor: F. Hoffmann-La Roche.

2019 – ongoing “A Phase III, Randomized Study of Nivolumab (Opdivo) plus AVD or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age ≥ 12 Years) with Newly diagnosed Advanced Stage Classical Hodgkin Lymphoma.” Sponsor: NCI CIRB

2019 – 2020      “ A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapeis.”  Sponsor: MEI Pharma Inc

2019 – ongoing “An Open label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K d/g Dual Inhibitor, Given in Combination with a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients with Relapsed/Refractory T cell Lymphoma.”  Sponsor: Rhizen Pharmaceuticals

2020 – ongoing “Randomized Phase II/III Study of Venetoclax (ABT 199) plus Chemoimmunotherapy for Myc/BCL2 Double-Hit and Double Expressing Lymphoma” Sponsor: Alliance for Clinical Trials in Oncology

2020 – ongoing “Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas” Sponsor: Astex Pharmaceuticals

Invited Lectures, Conference Presentations or Professorships:

International and National (Past 10 years only)

8/11/2009        “Epigenetics, New Insights into Cancer”, Nebraska Oncology Society, Omaha Nebraska

02/01/2010      “ONTAK (denileukin diftitox) – Results from the Largest Phase III Randomized, Placebo-Controlled, Double Blinded Trial in CTCL” Medical Oncology-Hematology Division Ground Rounds, Rush University, Chicago IL

1/9/2012          “Cutaneous T cell lymphoma (CTCL) and the Role of Extracorporeal Photopheresis (ECP)”  North Shore University Hospital, New York, NY

Regional and Local (Past 10 years only)

5/13/2009        “What’s new in the treatment of Non-Hodgkin lymphoma” at the Leukemia & Lymphoma Patient Education Talks. Portland, Oregon

11/23/2009      “Introduction to Lymphoproliferative Disorders” at the Internal Medicine House Staff Noon Lectures

12/10/2009      “Follicular Lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR

1/22/2010        “Update in Lymphoma” at the 10^th Annual Hematology and Breast Cancer Update, Portland Oregon

1/29/2010        “Marginal Zone Lymphomas” at the OHSU Hematology/Oncology Fellow’s Grand Rounds, Portland OR

2/25/2010        “Reprograming Gene Expression and Protein Activity: Insights on Histone Deacetylase in Cancer” Coos Bay, Oregon

4/24/2010        “Chronic Lymphocytic Leukemia 2009-2010” at the Leukemia & Lymphoma Patient Education Seminar, Portland, Oregon

9/6/2010          “HDAC inhibitors for Cutaneous T Cell Lymphoma”, Salem Oregon

1/14/2011        “Update in Lymphoma” at the 11th Annual Hematology and Breast Cancer Update, Portland Oregon

10/5/2011        “Imaging in Lymphoma” at the OHSU Leukemia and Lymphoma Conference, Portland OR

12/21/2011      “T cell Lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR

1/20/2012        “Update in Lymphoma” 12th Annual Hematology and Breast Cancer Update, Portland Oregon

1/31/2012        “Introduction to Lymphoproliferative Disorders” at the Internal Medicine House Staff Noon Lectures.

3/14/2012        “Burkitt’s Lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR

3/21/2012        “Update on Cutaneous Lymphoma” at the Oregon Dermatology Society Meeting.

7/18/2012        “Paraneoplastic Neuropathy” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR

11/8/2012        “Indolent Lymphoma” at the OHSU Hematology/Oncology Fellow’s Grand Rounds, Portland OR

11/8/2012        “Ask about Lymphoma” at the Lymphoma Research Foundation Patient Education forum, Portland, Oregon

12/12/2012      “Peripheral T cell lymphoma” OHSU Community Oncology, Beaverton OR

12/18/2012      “Lymphoma Treatment in Pregnant Patients” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR

1/18/2013        “Update in Lymphoma” at the 13th Annual Hematology and Breast Cancer Update , Portland Oregon

4/22/2013        “Lymphoma Treatment in Pregnant Patients” at the Maternal Fetal Medicine Conference, OSHU, Portland, Oregon

4/25/2013        “T cell Lymphoma” at the OHSU Hematology/Oncology Fellow’s Grand Rounds, Portland OR

6/26/2013        “CNS Lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR

9/18/2013        “Immunotherapy Treatments for Lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR

5/14/2014        “Chemotherapy and Radiation Treatment of Lymphoma” at the Radiation Oncology Lecture Series, OHSU, Portland, Oregon

5/28/2014        “Update on Cutaneous T Cell Lymphoma” at the City Wide Dermatology Conference, OHSU, Portland, Oregon

7/17/2014        “Introduction to Lymphoma” at the OHSU Oncology Nurses Education series, Portland OR

10/8/2014        “Post Transplant Lymphoproliferative Disorder” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR

11/14/14          “Indolent Lymphoma” at the OHSU Hematology/Oncology Fellow’s Grand Rounds, Portland OR

1/7/2015          “Epstein Bar Virus (EBV) infections and Hemophagocytic lymphohistiocytosis (HLH)” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR

1/16/2015        “Update in Lymphoma” at the 14th Annual Hematology and Breast Cancer Update, Portland Oregon

1/23/2015        “T cell Lymphoma” at the OHSU Hematology/Oncology Fellow’s Grand Rounds, Portland OR

1/29/2015        “Updates from ASH” at the S.W. Washington Oncology Journal Club, , Vancouver WA.

4/6/2015          “Hematology as a Career” at the OHSU Medical Student Oncology Interest Group, Portland OR

4/23/2015        “Post Organ Transplant Malignancies and Cancer screening” at the OHSU Combined Transplant Grand Rounds. OHSU Hospital, Portland OR

6/24/2015        “Hodgkin Lymphoma – Management and New Treatments” at the Legacy Hospital Oncology Grand Rounds. Good Samaritan Medical Center, Portland OR

7/6/2015          “Introduction to Hematology Procedures” at the OHSU Hematology/Oncology Fellowship Orientation week, Portland OR

11/06/2015      “Low grade Lymphoma” at the OHSU Hematology/Oncology Fellow’s Grand Rounds, Portland OR

11/07/2015      “How to Write a Grant” OHSU Fellowship Research Conference, Skamania Lodge, Stevenson, WA 

1/15/2016        “Update in Lymphoma” at the 14th Annual Hematology and Breast Cancer Update, Portland Oregon

1/20/2016        “CNS Lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR

2/2/2016          “Lymphoma and Chemotherapy” at the Radiation Oncology Lecture Series, OHSU, Portland, Oregon

6/8/2016          “Burkitt’s lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR

7/5/2016          “Introduction to Hematology Procedures” at the OHSU Hematology/Oncology Fellowship Orientation week, Portland OR

6/23/2017        “Hematologic Malignancies – 2017 Updates in Oncology Conference” Sentinel Hotel, Portland OR

7/10/2017        “Introduction to Hematology Procedures” at the OHSU Hematology/Oncology Fellowship Orientation week, Portland OR

8/30/2017        “Treatments for Cutaneous T cell Lymphoma” at the Cutaneous Lymphoma Foundation Patient Education Forum, Portland, OR

1/19/2018        “Update in Lymphoma” at the 16th Annual Hematology and Breast Cancer Update, Portland Oregon

7/20/2018        “Hematologic Malignancies – 2018 Updates in Oncology Conference” Sentinel Hotel, Portland OR

1/18/2019        “Update in Lymphoma” at the 17th Annual Hematology and Breast Cancer Update, Portland Oregon

6/14/2019        “Hematologic Malignancies – 2019 Updates in Oncology Conference” Sentinel Hotel, Portland OR

11/20/2019      “Hodgkin Lymphoma” at OHSU CME Talks, Portland OR

11/27/2019      “B cell lymphoma” at OHSU CME Talks, Portland OR

V.  SERVICE

Membership in Professional Societies:

1986 - 2000        American Medical Association

1991 - ongoing   American College of Physicians

1993 - ongoing   American Society of Hematology

1994 - ongoing   American Association for the Advancement of Science

1998 -2005         American Society of Clinical Oncology

2000 - 2004        Central Society for Clinical Research

2012 - ongoing   Oregon Medical Society

Granting Agency Review Work:

2/2000                NIH Ad Hoc Member Site Visit Review - Memorial Sloan Kettering Cancer Center Gene Therapy Program, New York NY

11/2010              NIH PAR 01-045 and PAR 01-046, Cancer Molecular Target Drug Discovery, Bethesda MD

10/2012              NIH PAR 12-144, Cancer Molecular Target Drug Discovery, Bethesda MD

3/2010 - 4/2014 NIH SBIR Topic 255, Development of Anticancer Agents Technical Emphasis Panel, Bethesda MD

6/15/2016           NIH SBIR  Topic 326: Development of Novel Therapeutic Agents that Target Cancer Stem Cells

11/15/2018         NIH SBIR Phase IIB Bridge Awards – Cancer Therapeutics and Preventative Agents, Cancer Imaging Technologies. Interventional Devices.

Editorial and Ad Hoc Review Activities:

2001 - 2009     Online Update Editor for Kelly Textbook of Internal Medicine

2007 - 2011     Ad Hoc Reviewer for International Journal of Laboratory Hematology

2007 - 2010     Ad Hoc Reviewer for Cancer Letters

2010 - 2011     Ad Hoc Reviewer for Blood

2014                Ad Hoc Reviewer for Journal of Hematology Research

Committees:

International/National

Regional

Institutional

1998 - 2004      Member, Blood Utilization Committee, Veteran Administration Ann Arbor Healthcare Systems

1999 - 2004      Member, Immunology Graduate Program, University of Michigan

1999 - 2004      Member, Tumor Immunology Program, University of Michigan

2000 - 2004      Member, MSTP Career Advisory Panel, University of Michigan

2002 - 2004      Member, Cancer Committee, Veteran Administration Ann Arbor Healthcare Systems

2002 - 2004      Member, Research and Development Committee, Veteran Administration Ann Arbor Healthcare System, Ann Arbor, MI

2005 - 2006      Alternate Member, Research and Development Committee, VA Portland Health Care System, Portland, Oregon

2007 - 2010      Member, Research and Development Committee, VA Portland Health Care System, Portland, Oregon

2010 - 2013      Alternate Member, Research and Development Committee, VA Portland Health Care System, Portland, Oregon

2011 - ongoing Member, Clinic Research Review Committee, Oregon Health & Sciences University, Portland, Oregon

2012 - ongoing Member, Joint OHSU/VA Institutional Review Board, Oregon Health & Sciences University and VA Portland Health Care System, Portland, Oregon

2013 - 2018      Member, Pharmacy and Therapeutics – Oncology Subcommittee. Oregon Health and Sciences University

2014 - 2016      Member, Pharmacy and Therapeutic Committee, VA Portland Health Care System, Portland, OR

2018 - ongoing Co-chair, Pharmacy and Therapeutics – Oncology Subcommittee. Oregon Health and Sciences University

2018 - ongoing Member, Clinical Knowledge and Therapeutics Executive Committee, Oregon Health and Science University

Departmental

2007 - 2015      Member, Hematology-Oncology Fellowship Selection Committee, Oregon Health and Science University, Portland, Oregon

2007 - ongoing Interviewer, Intern Applicants, Department of Intern. Med., Oregon Health and Science University, Portland, Oregon

2009 - ongoing Lead, Lymphoma Tumor Board, Oregon Health and Science University, Portland OR

Community Service:

Patient education forums:

9/16/2000        Cure for Lymphoma Living Well with Lymphoma Family Forum “Orphan Lymphomas”  Novi, MI

5/23/2001        "Ask the Doctor about Lymphoma" Gilda's Club, Royal Oak, MI

10/10/2007      OHSU and Cutaneous Lymphoma Foundation Patient Education Forum “Cutaneous Lymphomas Overview” and “CTCL Diagnosis, Staging and Prognosis”. Portland, Oregon

5/13/2009        Leukemia & Lymphoma Patient Education Talk. “What’s new in the treatment of Non-Hodgkin lymphoma” Portland, Oregon

4/24/2010        Leukemia & Lymphoma Patient Education Symposium, “Chronic Lymphocytic Leukemia 2009-2010” Portland, Oregon

11/8/2012        Lymphoma Research Foundation “Ask about Doctor” Update on Follicular Lymphoma. Center for Health and Healing, Portland, Oregon

2/21/2017        Lymphoma Research Foundation “Ask the Doctor” Update on Mantle Cell Lymphoma, Portland Oregon

3/15/2017        Cutaneous Lymphoma Foundation Patient Education Forum “Update in Cutaneous T cell Lymphoma”. Tualitin, Oregon

8/30/2017        “Treatments for Cutaneous T cell Lymphoma” at the Cutaneous Lymphoma Foundation Patient Education Forum, Portland, OR

6/23/2019        Clinical Trials in Cutaneous Lymphoma” at the Cutaneous Lymphoma Foundation Patient Education Forum, Los Angles, CA

Clinical Responsibilities (since last promotion):

9/1998 - 1/2004    Staff Physician, Hematology Outpatient Clinic, VA Ann Arbor Healthcare System, Ann Arbor, MI

9/1999 - 1/2004    Attending Physician, Hematology Consult Service, University of Michigan

9/1999 - 1/2004    Staff Physician, Hematology Consult Service, VA Ann Arbor Healthcare System

9/1999 - 1/2004    Attending Physician, Lymphoma Multidisciplinary Clinic, Univ. of Mich.

10/2000 - 1/2004  Attending Physician, Cutaneous T cell Lymphoma Clinic, Univ. of Mich.

2/2004 – 10/2017  Staff Physician, Hospital and Specialty Medicine - Hematology, VA Portland Health Care System, Portland, OR

7/2004 - ongoing  Attending Physician, Hematology Consult Service and Malignant Hematology Service, Oregon Health & Science University, Portland, OR

7/2004 - ongoing  Attending Physician, Cutaneous Lymphoma Clinic, Oregon Health & Sciences University, Portland, OR

6/2007 - ongoing  Attending Physician, Lymphoma Clinic, Oregon Health & Sciences University, Portland, OR

6/2009 - ongoing  Attending Physician, Malignant Hematology Inpatient Hospital Service, Oregon Health & Science University, Portland, OR

7/2015 – 10/2017  Staff VA Portland Health Care System Hem/Onc Fellow’s clinic

VI.  TEACHING:

Overview of your Role as an Educator: (see OHSU Educators Portfolio)

5/24/2019        Faculty Teaching Award from the Internal Medicine Housestaff

Scholarship of Teaching:

Curriculum Development

2015 – Member, Hematology and Medical Oncology Fellowship Curriculum Committee, Oregon Health & Science University

Educational Publications

Educational Conference Presentations

Education Grants and Contracts:

Educational Activity (see Appendix A and B):

1999 - 2003        Lecturer, Hematology/Oncology Research Conference, “TCR Idiotype Vaccine for the Treatment of T cell Malignancies.” University of Michigan

1999 - 2003        Lecturer, Hematology Noon Conference, “Cases from the Hematology Consult Service” University of Michigan

2001- 2003         Group Leader, PIBS 501 – Research Responsibility, University of Michigan

2002                   Lecturer, Internal Medicine Noon Conference, “Approach to the Patient with Thrombocytopenia”, University of Michigan

2002                   Lecturer, Immunology 850 - Special Topics in Immunology, “Idiotype Vaccines for Treatment of Lymphoid Malignancies”. University of Michigan

2004 - 2014        Lecturer and small group session leader, Pathophysiology of Blood, Oregon Health & Science University

2005 - ongoing   Clinic Mentor for PCM student (1^st and 2^nd year medical student), Oregon Health & Sciences University

2007 - 2013        Small group session leader, Biologic Basis of Disease, Oregon Health & Science University

2007 - 2010        Lymphoma case conference –Every other week conference on interesting lymphoma cases. Oregon Health & Science University

2007 - ongoing   Lecturer, Noon Conference for Internal Medicine Housestaff, Lecture on Lymphoma. Oregon Health & Science University.

2007 - ongoing   Lecturer, Hem-Onc Fellow Grand Rounds, Oregon Health & Science University

2009 - ongoing   Lecturer, Medical Student Core Lectures, Oregon Health & Science University
- Introduction to lymphoproliferative disorders
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia (occasionally)

2009 - ongoing   Lead, Lymphoma Tumor Board, Oregon Health & Science University

2009 - ongoing   Lecture in Cancer Biology CELL616 course

2009 - ongoing   Lecture, Noon Conference for Dermatology Housestaff, Oregon Health & Science University

2011- ongoing    Speaker, Center for Hematologic Malignancy Grand Rounds, Oregon Health & Science University

12/16/2014         “Ward walk” with 1^st and 2^nd year medical students

Effectiveness of Educational Activity:

Service and Membership of Educational Committees:

2007- 2017         Hematology and Medical Oncology Fellowship committee

Honors and Awards for Education:

2015          OHSU Hematology and Medical Oncology Annual Teaching Award

Collaborative Skills:

Professional Development in Education: